Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.

Click to increase image sizeClick to decrease image size Disclosure statementNo potential conflict of interest was reported by the author(s).Additional informationFundingThis work was supported by the University of Washington/Fred Hutch Cancer Consortium grant NCI 5 P30 CA015704-47. Additional funding was provided to NEK through the NHLBI T32 training grant (T32 HL007093).